Table 1 Clinical characteristics of the head and neck squamous cell carcinoma cohort
169 patients with available pre-RCT biopsies | |
Gender | |
Male | 140 (82.8%) |
Female | 29 (17.2%) |
Age | <56.4: 85 (50.3%) >56.4: 84 (49.7%) |
T-Stage | |
T1 | 38 (24.2%) |
T2 | 58 (36.9%) |
T3 | 29 (18.5%) |
T4 | 32 (20.4%) |
N-Stage | |
N0 | 33 (21%) |
N1 | 48 (30.6%) |
N2 | 69 (43.9%) |
N3 | 7 (4.5%) |
M-Stage | |
M0 | 132 (98.5%) |
M1 | 2 (1.5%) |
Grading | |
G1 | 9 (5.7%) |
G2 | 90 (56.6%) |
G3 | 60 (37.7%) |
Localization of tumor | |
Oropharynx | 83 (49.1%) |
Base of the mouth | 79 (46.8%) |
Alveolar ridge | 7 (4.1%) |
Radiotherapy | |
Neoadjuvant | 32 (18.9%) |
Adjuvant | 137 (81.1%) |
Mean total dose | 59.2 Grey |
Mean dose per fraction | 2.0 Grey |
Chemotherapy | |
None | 49 (29%) |
5-FU + Cisplatin | 93 (55%) |
5-FU + Carboplatin | 9 (5.3%) |
Others | 18 (10.7%) |
32 patients with available post-RCT biopsies | |
Gender | |
Male | 28 (87.5%) |
Female | 4 (12.5%) |
Age | <51.4: 71 (46.4%) >51.4: 82 (53.6%) |
T-stage | |
T1 | 2 (6.3%) |
T2 | 10 (31.2%) |
T3 | 8 (25%) |
T4 | 12 (37.5%) |
N-Stage | |
N0 | 11 (34.4%) |
N1 | 21 (65.6%) |
M-Stage | |
M0 | 32 (100%) |
Grading | |
G1 | 1 (3.7%) |
G2 | 21 (77.8%) |
G3 | 5 (18.5%) |
Localization of tumor | |
Oropharynx | 8 (25.0%) |
Base of the mouth | 23 (71.9%) |
Alveolar ridge | 1 (3.1%) |
Radiotherapy | |
Neoadjuvant | 32 (100%) |
Mean total dose | 50.1 Grey |
Mean dose per fraction | 1.8 Grey |
Chemotherapy | |
None | 1 (3.1%) |
5-FU + Cisplatin | 29 (90.6%) |
5-FU + Carboplatin | 2 (6.3%) |